American Hemp Growers met Thursday with representatives for the congressional subcommittee on Biotechnology, Horticulture, and Research.
The intent of the meeting was to convey our desire to testify if the Hemp Advancement Act comes before the subcommittee for a hearing.
Last week, the same subcommittee held a hearing to review the rollout of the 2018 hemp program. Despite requesting an opportunity to testify almost immediately after the hearing was announced, American Hemp Growers was informed that the witnesses for the hearing had already been selected.
Among those selected witnesses was a representative for the US Hemp Roundtable. The Roundtable made clear in the hearing that it wants hemp-derived THCs banned.
In our meeting, we explained that the Roundtable does not speak for the majority of the hemp industry. We further explained that many retailers, manufacturers, processors and small farms would be irreparably damaged if the Hemp Advancement Act becomes law.
Major changes to the hemp program are expected to be included in the 2023 Farm Bill – the drafting of which is expected to begin in early 2023. Most notably, “synthetically derived” hemp THCs would not be allowed in interstate commerce and would be capped at 0.3% total THC intrastate. This capping of the finished products at 0.3% total THC will also have the side effect of banning consumer CBD flower.
AHG has requested to be given consideration to testify at future hearings as these changes are considered.
In the interim, congress is currently receiving feedback about the upcoming Farm Bill. You should take the time to submit brief feedback concerning the Hemp Advancement Act and how it will impact your business.